BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35195881)

  • 21. Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study.
    Chen X; Cui X; Pognan N; Quinlan M; Kapoor S; Rahmanzadeh G; Giovannini M; Marbury TC
    Br J Clin Pharmacol; 2022 Jan; 88(1):91-102. PubMed ID: 34046915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
    Ramalingam SS; O'Byrne K; Boyer M; Mok T; Jänne PA; Zhang H; Liang J; Taylor I; Sbar EI; Paz-Ares L
    Ann Oncol; 2016 Mar; 27(3):423-9. PubMed ID: 26768165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants.
    Fan B; Dai D; Cohen M; Xu H; Yin F; Nagaraja R; Mobilia M; Almon C; Basile FG; Yang H
    Clin Pharmacol Drug Dev; 2021 Jan; 10(1):99-109. PubMed ID: 32648303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Chawla A; Rosell R; Corral J; Migliorino MR; Pluzanski A; Noonan K; Tang Y; Pastel M; Wilner KD; Wu YL
    Drugs; 2021 Feb; 81(2):257-266. PubMed ID: 33331989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment.
    Jogiraju V; Weber E; Hindman J; West S; Ling J; Rhee M; Girish S; Palaparthy R; Singh R
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0134423. PubMed ID: 38456707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
    Lavacchi D; Mazzoni F; Giaccone G
    Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment.
    Lin S; Gong J; Canas GC; Winkle P; Pelletier K; LaBadie RR; Ginman K; Pithavala YK
    Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):235-245. PubMed ID: 35018553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
    Reckamp KL; Giaccone G; Camidge DR; Gadgeel SM; Khuri FR; Engelman JA; Koczywas M; Rajan A; Campbell AK; Gernhardt D; Ruiz-Garcia A; Letrent S; Liang J; Taylor I; O'Connell JP; Jänne PA
    Cancer; 2014 Apr; 120(8):1145-54. PubMed ID: 24501009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.
    Yu HA; Ahn MJ; Cho BC; Gerber DE; Natale RB; Socinski MA; Giri N; Quinn S; Sbar E; Zhang H; Giaccone G
    Lung Cancer; 2017 Oct; 112():195-199. PubMed ID: 29191595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
    Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
    Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
    Tayo B; Taylor L; Sahebkar F; Morrison G
    Clin Pharmacokinet; 2020 Jun; 59(6):747-755. PubMed ID: 31802404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.
    Jensen L; Kupcova V; Arold G; Pettersson J; Hjerpsted JB
    Diabetes Obes Metab; 2018 Apr; 20(4):998-1005. PubMed ID: 29205786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
    Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.
    Abel S; Davis JD; Ridgway CE; Hamlin JC; Vourvahis M
    Antivir Ther; 2009; 14(6):831-7. PubMed ID: 19812445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.
    Wang J; Wang X; Zhang ZY; Arora S; Lu S; Kansra V
    J Clin Pharmacol; 2018 May; 58(5):686-693. PubMed ID: 29329482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
    Nishio M; Kato T; Niho S; Yamamoto N; Takahashi T; Nogami N; Kaneda H; Fujita Y; Wilner K; Yoshida M; Isozaki M; Wada S; Tsuji F; Nakagawa K
    Cancer Sci; 2020 May; 111(5):1724-1738. PubMed ID: 32159882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
    Chavan A; Burke L; Sawant R; Navarro-Gonzales P; Vargo D; Paulson SK
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):950-958. PubMed ID: 33661566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.
    Wiebe S; Schnell D; Külzer R; Gansser D; Weber A; Wallenstein G; Halabi A; Conrad A; Wind S
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):461-469. PubMed ID: 27436099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of dose modifications on the safety and efficacy of dacomitinib for
    Corral J; Mok TS; Nakagawa K; Rosell R; Lee KH; Migliorino MR; Pluzanski A; Linke R; Devgan G; Tan W; Quinn S; Wang T; Wu YL
    Future Oncol; 2019 Aug; 15(24):2795-2805. PubMed ID: 31313942
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.